Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 2/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | LOX | P28300 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31119651 | 0.82 | KIF11 (0.54) | SYKNOTUMIDO1KIF11LOXL2 | |
| SCHEMBL15859932 | 0.81 | NOTUM (0.49) | NOTUMIDO1KIF11LOXL2AR | |
| SCHEMBL31375563 | 0.81 | NOTUM (0.49) | NOTUMIDO1KIF11LOXL2AR | |
| SCHEMBL1690559 | 0.80 | NOTUM (0.44) | SYKNOTUMIDO1LOXL2LOX | |
| SCHEMBL29769017 | 0.78 | LOXL2 (0.52) | SYKNOTUMIDO1LOXL2AR | |
| SCHEMBL1199840 | 0.78 | LOXL2 (0.52) | SYKNOTUMIDO1LOXL2AR | |
| SCHEMBL28913750 | 0.78 | IDO1 (0.53) | NOTUMIDO1LOXL2LOXMAP4K4 | |
| SCHEMBL27893421 | 0.78 | NOTUM (0.49) | SYKNOTUMIDO1KIF11LOXL2 | |
| SCHEMBL30112180 | 0.78 | IDO1 (0.53) | NOTUMIDO1LOXL2LOXMAP4K4 | |
| SCHEMBL10259946 | 0.77 | LOXL2 (0.67) | SYKNOTUMIDO1LOXL2LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122173-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LTD (GB) | 2025-04-17 | — | — | US | disclosed |
| EP-4466071-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) | Redx Pharma Limited (GB) | 2024-11-27 | — | — | EP | disclosed |
| CN-118632845-A | Modulators of Rho-associated protein kinase (ROCK) | 莱德克斯制药有限公司 | 2024-09-10 | — | — | CN | disclosed |
| WO-2023139379-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) | REDX PHARMA PLC (GB) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139379-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) | REDX PHARMA PLC (GB) | 2023-07-27 | — | — | WO | disclosed |
| EP-2590951-B1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2015-01-07 | — | — | EP | disclosed |
| EP-2590951-B1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2015-01-07 | — | — | EP | disclosed |
| US-8772293-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2014-07-08 | — | — | US | disclosed |
| US-8772293-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2014-07-08 | — | — | US | disclosed |
| US-8772293-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2014-07-08 | — | — | US | disclosed |
| EP-2590951-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | Pfizer Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004743-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004743-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010182-A1 | Chemical Compounds | ICAGEN INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010182-A1 | Chemical Compounds | ICAGEN INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010182-A1 | Chemical Compounds | ICAGEN INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010182-A1 | Chemical Compounds | SCN1A, SCN1B, CACNA1E | SYK 577/4885NOTUM 3342/4885IDO1 3996/4885 |
| US-20250122173-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK1, ROCK2, RHOA | SYK 892/4885NOTUM 3392/4885IDO1 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.